Abstract
AbstractThis first Phase III study on a topical inhibitor of corneal angiogenesis showed aganirsen eye drops to significantly inhibit corneal neovascularization in patients with keratitis. The need for transplantation was significantly reduced in patients with viral keratitis and central neovascularization. Topical application of aganirsen was safe and well‐tolerated.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call